{"title":"HYVET研究:回答是否要治疗老年高血压的问题","authors":"S. Jarvis","doi":"10.3132/PCCJ.2008.025","DOIUrl":null,"url":null,"abstract":"prematurely on the basis of overwhelming benefit in the treatment arm. Treatment was associated with a 39% reduction in stroke mortality rate (p=0.05) and a 64% reduction in heart failure (p 80 years with a sustained systolic BP > 160 mmHg to the diuretic indapamide slow release (SR) 1.5 mg or matching placebo. The angiotensin-converting enzyme (ACE) inhibitor perindopril (2–4 mg), or matching placebo, were added as necessary to achieve a target blood pressure of 150/80 mmHg.","PeriodicalId":308856,"journal":{"name":"Primary Care Cardiovascular Journal (pccj)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The HYVET study: answering the question of whether or not to treat hypertension in the very elderly\",\"authors\":\"S. Jarvis\",\"doi\":\"10.3132/PCCJ.2008.025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"prematurely on the basis of overwhelming benefit in the treatment arm. Treatment was associated with a 39% reduction in stroke mortality rate (p=0.05) and a 64% reduction in heart failure (p 80 years with a sustained systolic BP > 160 mmHg to the diuretic indapamide slow release (SR) 1.5 mg or matching placebo. The angiotensin-converting enzyme (ACE) inhibitor perindopril (2–4 mg), or matching placebo, were added as necessary to achieve a target blood pressure of 150/80 mmHg.\",\"PeriodicalId\":308856,\"journal\":{\"name\":\"Primary Care Cardiovascular Journal (pccj)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Primary Care Cardiovascular Journal (pccj)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3132/PCCJ.2008.025\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Primary Care Cardiovascular Journal (pccj)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3132/PCCJ.2008.025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The HYVET study: answering the question of whether or not to treat hypertension in the very elderly
prematurely on the basis of overwhelming benefit in the treatment arm. Treatment was associated with a 39% reduction in stroke mortality rate (p=0.05) and a 64% reduction in heart failure (p 80 years with a sustained systolic BP > 160 mmHg to the diuretic indapamide slow release (SR) 1.5 mg or matching placebo. The angiotensin-converting enzyme (ACE) inhibitor perindopril (2–4 mg), or matching placebo, were added as necessary to achieve a target blood pressure of 150/80 mmHg.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
